Determining cell type abundance and expression from bulk tissues with digital cytometry

Aaron M. Newman1,2*, Chloé B. Steen3,4, Chih Long Liu1,2, Andrew J. Gentles2,3,5,6, Aadel A. Chaudhuri7,8, Florian Scherer3,9, Michael S. Khodadoust3, Mohammad S. Esfahani3,5,8, Bogdan A. Luca6, David Steiner3, Maximilian Diehn1,6,8 and Ash A. Alizadeh1,3,5,8,9*

Single-cell RNA-sequencing has emerged as a powerful technique for characterizing cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be applied to fixed specimens collected as part of routine clinical care. We previously developed an approach for digital cytometry, called CIBERSORT, that enables estimation of cell type abundances from bulk tissue transcriptomes. We now introduce CIBERSORTx, a machine learning method that extends this framework to infer cell-type-specific gene expression profiles without physical cell isolation. By minimizing platform-specific variation, CIBERSORTx also allows the use of single-cell RNA-sequencing data for large-scale tissue dissection. We evaluated the utility of CIBERSORTx in multiple tumor types, including melanoma, where single-cell reference profiles were used to dissect bulk clinical specimens, revealing cell-type-specific phenotypic states linked to distinct driver mutations and response to immune checkpoint blockade. We anticipate that digital cytometry will augment single-cell profiling efforts, enabling cost-effective, high-throughput tissue characterization without the need for antibodies, disaggregation or viable cells.
We started by generating a scRNA-seq library from peripheral blood mononuclear cells (PBMCs) obtained from a patient with non-small cell lung cancer (NSCLC) using 10x Genomics Chromium v2 (3′ assay). Unsupervised clustering and canonical marker gene assessment revealed six major leukocyte subsets (B cells, CD4 T cells, CD8 T cells, NKT cells, NK cells and monocytes; Fig. 2a). To assess deconvolution performance, we built a signature matrix to distinguish these cell subsets and tested it on a validation cohort of bulk RNA-sequencing (RNA-seq) profiles of blood obtained from 12 healthy adults (Supplementary Tables 1 and 2).

Compared with ground truth cell proportions as determined by direct cytometry and fluorescence immunophenotyping, uncorrected deconvolution results showed clear estimation biases for some cell types in bulk admixtures (Fig. 2b and Supplementary Fig. 1d). We hypothesized that these biases could be driven by platform-specific variation between the signature matrix and bulk RNA-seq data, as might be introduced, for example, by the variable use of unique molecular identifiers (UMIs) during library preparation. Indeed, following application of a batch correction scheme that we developed (Supplementary Fig. 1a, Supplementary Note 1 and Methods), deconvolution results substantially improved and compared favorably with ground truth cell proportions (Fig. 2b and Supplementary Fig. 1d). We observed similar gains in performance through batch correction when analyzing other datasets and signature matrices, including publicly available Chromium v2 PBMC data (3′ and 5′ kits; Supplementary Fig. 2a–c) and purified leukocyte subsets profiled using microarrays (Supplementary Fig. 2d). Given these systematic improvements, we therefore applied batch correction in all subsequent cross-platform analyses, unless stated otherwise (Supplementary Table 1).

We next extended our analysis to solid tumor biopsies, where single cells were profiled by SMART-Seq2. Focusing on head and neck squamous cell carcinomas (HNSCC) and melanomas (n = 18 and 19 patients, respectively), we initially tested deconvolution performance on simulated tumors reconstructed from single cells. This allowed us to evaluate the utility of single-cell reference profiles in a manner that controlled for dissociation-related artifacts and heterogeneity in phenotypic definitions. In a dataset of 18 primary tumors and 5 lymph node metastases from patients with HNSCC, we created a signature matrix from a training cohort consisting of 2 primary tumor specimens and 1 lymph node biopsy (Supplementary Table 2). This matrix distinguished malignant cells, CD4 and CD8 T cells, B cells, macrophages, dendritic cells, mast cells, endothelial cells, myocytes and cancer-associated fibroblasts (Fig. 2c). When evaluated using reconstructed tumor samples, deconvolution results were highly concordant with ground truth cell proportions (Fig. 2d and Supplementary Fig. 3a). Strong performance was also maintained when considering deconvolution results across distinct tumor types and cell types, including within rare or difficult to isolate cell subpopulations, such as distinct CD8 T cell effector subsets infiltrating melanomas (Supplementary Figs. 3b–d and 4 and Supplementary Table 2).

**Fig. 1 | Framework for in silico cell enumeration and purification.** A typical CIBERSORTx workflow involves a serial approach, in which molecular profiles of cell subsets are first obtained from a small collection of tissue samples and then repeatedly used to perform systematic analyses of cellular abundance and gene expression signatures from bulk tissue transcriptomes. This process involves: (1) transcriptome profiling of single cells or sorted cell subpopulations to define a signature matrix consisting of barcode genes that can discriminate each cell subset of interest in a given tissue type; (2) applying the signature matrix to bulk tissue RNA profiles in order to infer cell type proportions; (3) representative cell type expression signatures; and (4) purifying multiple transcriptomes for each cell type from a cohort of related tissue samples. Using metastatic melanomas as an example, Fig. 6 illustrates the application of each step.
Fig. 2 | Bulk tissue deconvolution with single-cell reference profiles. a, Left: t-SNE projection of scRNA-seq data from the peripheral blood of a patient with NSCLC, with six major leukocyte populations indicated. Right: heat map of signature matrix genes distinguishing these six subsets. b, Enumeration of leukocyte frequencies in RNA-seq profiles of whole blood (n = 12 healthy adults) using the PBMC signature matrix from a, shown before and after cross-platform normalization. Performance gains are shown as Pearson correlations and assessed for each sample across five cell types defined by flow cytometry and automated whole blood counts (CBCs): B cells, NK cells, CD8 T cells, CD4 T cells, monocytes, and mast cells. Statistical significance was determined using a two-sided Wilcoxon signed-rank test. Data are presented as boxplots (n = 12 per group; center line, median; box limits, upper and lower quartiles; whiskers, maximum and minimum values). c, t-SNE projection of scRNA-seq data from 23 HNSCC tumors (left) and training/validation approach for assessing single-cell deconvolution performance (right). d, Concordance between cell type proportions measured by scRNA-seq and CIBERSORTx deconvolution for 20 held-out HNSCC tumors for validation from c. All tumor GEPs were reconstructed from single-cell data. e, Analysis of cell subset enumeration across diverse signature matrices, tissues, and platforms. Deconvolution was run with batch correction (Methods). Ground truth cell proportions were determined by scRNA-seq (HNSCC, melanoma) or by flow cytometry and automated hematology leukocyte differential counter (blood). Cell subsets within the gray band are significantly concordant with ground truth by Pearson correlation (P < 0.05). Signature matrices are provided in Supplementary Table 2, with the exception of LM22 (ref. 19). Data are presented as medians ± interquartile range. Additional details are provided in Supplementary Note 1. f, Left: t-SNE plot of pancreatic islet subsets from ten human subjects, five of which were profiled by scRNA-seq, bulk RNA-seq and IHC21 (also see Supplementary Fig. 3f–i). Right: scatter plots depicting concordance between the frequencies of four major islet subsets quantitated by IHC versus scRNA-seq (top) and CIBERSORTx deconvolution of bulk RNA-seq (bottom), as determined by linear regression. The significance of the result was assessed by a two-sided t-test. Mono, monocytes; Macs, macrophages; DNs, dendritic cells; Mast, mast cells; Endo, endothelial cells; Myo, myocytes; NS, not significant.

To explore the impact of key signature matrix-related parameters on single cell-guided deconvolution, we next examined CIBERSORTx performance as a function of the number of cells per phenotype, the number of donor samples and the number of genes considered. Across a range of values for these factors, we observed a surprisingly modest effect on cell proportion estimates (Supplementary Fig. 5a–c). Moreover, regardless of their primary biological source, CIBERSORTx signature matrices exhibited strong generalizability across diverse expression profiling platforms, datasets and tissues after batch correction was applied (Fig. 2e).

Leveraging the single cell-derived signature matrix from melanoma biopsies described above, we then applied CIBERSORTx to dissect melanoma RNA-seq profiles from The Cancer Genome Atlas (TCGA)17. We observed substantial differences in the fractional representation of B/T lymphocytes and macrophages when comparing predicted cell type proportions in bulk tumors and the original scRNA-seq results (Supplementary Fig. 3e). Since these cell subsets were unscored relative to one another in the scRNA-seq dataset10, such compositional distortions may have arisen either from technical artifacts due to single-cell isolation and sequencing18,19 or from the deconvolution approach itself. In support of the former, IHC estimates of tumor-infiltrating leukocyte (TIL) subsets in an independent melanoma cohort22 were far more similar to TIL fractions estimated by CIBERSORTx than those determined by scRNA-seq (Supplementary Fig. 3e). Moreover, we observed the same distortion phenomenon in a dataset of human pancreatic islets profiled by scRNA-seq (SMART-Seq2), bulk RNA-seq and IHC21 (Fig. 2f and Supplementary Fig. 3f–i). In a direct comparison of paired islet subsets, cell fractions determined by IHC in bulk tissues were significantly correlated with bulk islet deconvolution results but not scRNA-seq (Fig. 2f and Supplementary Fig. 3i). These data further validate CIBERSORTx and highlight its value.
for mitigating dissociation-related distortions resulting from the physical isolation of intact single cells (for additional discussion, see Supplementary Note 2).

Cell-type-specific gene expression without physical cell isolation. Cell-type-specific transcriptome profiles can provide valuable insights into cell identity and function. However, such profiles are generally derived from single cells or bulk sorted populations, which can be difficult to obtain for large cohorts and fixed clinical samples. Even when purified cell types are available, tissue dissociation and preservation conditions can cause non-biological alterations in gene expression that obscure downstream analyses6,19. While mathematical separation of bulk tissue RNA profiles into cell-type-specific transcriptomes can potentially overcome these problems6,20–24, the accuracy of this technique on real tissue samples remains unclear. We therefore set out to evaluate whether a signature matrix, consisting of highly optimized marker genes, can be used to faithfully reconstruct cell-type-specific transcriptome profiles from non-disaggregated tissue samples, including fresh/frozen (FF) and fixed tumors (Fig. 3a).

We began by profiling 302 FF primary tumor biopsies from patients with untreated follicular lymphoma (FL) and tested a common approach25 in which cell type proportions are used to infer a single representative GEP for each cell type from a group of mixture samples (Methods). Since B cells, CD8 T cells and CD4 T cells comprise the vast majority of FL tumor cellularity and can be readily purified by FACS26, we focused on these three subsets to assess the accuracy of the approach. To enumerate FL immune proportions, we applied LM2215, a microarray-derived signature matrix for distinguishing 22 human hematopoietic cell subsets in bulk tissues, including tumors27. We started by examining B cells and CD8 T cells as examples of highly abundant and less abundant cell types in FL lymph nodes (>50% versus ~5–10%, respectively15). Although imputed and FACS-purified cell type transcriptomes were reasonably well correlated, considerable noise distorted expression estimates of many genes (Fig. 3b). We therefore developed an adaptive noise filter to eliminate unreliable estimated genes for each cell type (Fig. 3c). After implementing this strategy within CIBERSORTx, we observed consistently improved correlations between in silico purified transcriptomes and those from FACS-purified cells (Fig. 3d and Supplementary Fig. 6a).

We next investigated key factors that influence the accuracy of transcriptome purification (Fig. 3e and Supplementary Fig. 6). Using the set of 302 FL GEPs, we observed a predictable relationship between the number of tumors profiled and the accuracy of transcriptome imputation across B cells, CD4 T cells and CD8 T cells (Fig. 3e and Supplementary Fig. 6b). The largest gains were achieved when analyzing at least four–fivefold more mixture samples than cell types (Fig. 3e). Nevertheless, our filtration scheme uniformly improved performance over a previous approach25 irrespective of cohort size, the number of cell types, and overall cell type abundance (Fig. 3e and Supplementary Fig. 6b–e,g). We also observed favorable performance for resolving previously identified markers of cell identity and additional cell type transcriptomes (Fig. 3f,g and Supplementary Fig. 6d–h). As expected, the fraction of recovered genes after adaptive filtration was proportional to both the number of evaluated samples and the proportion of each cell subset (Supplementary Fig. 6h). Moreover, the use of different single cell-derived signature matrices did not significantly impact results, provided that identical cell types were interrogated (Supplementary Fig. 5c).

Cell-type-specific expression purification at high resolution. Having shown that cell-type-specific GEPs can be reliably estimated, we next turned to the problem of inferring cell-type-specific differential expression from bulk specimens. Despite the utility of the above technique, it is limited to learning a single representative expression profile for each cell type given a group of mixture samples (group-mode GEPs; Fig. 1). While useful for comparing two groups of specimens, such profiles are not sample-specific and must be generated for each group of interest in order to study differentially expressed genes (DEGs) between them. Although approaches for sample-level deconvolution have been previously described, they only consider mixtures with two or three cellular components22,23. We therefore developed a framework that generalizes to multiple (>3) components by modeling gene expression deconvolution as a unique non-negative matrix factorization problem with partial observations (Supplementary Fig. 7 and Methods). Briefly, our approach attempts to separate a single mixture of matrix GEPs into a set of underlying cell-type-specific expression matrices using imputed cell proportions (Fig. 4a,b). Once these expression profiles are obtained, they can be analyzed post hoc to gain insights into sample-level variation and patterns of gene expression for individual cell types of interest.

To solve the matrix factorization problem, we implemented a new divide and conquer algorithm that produces biologically realistic solutions (Supplementary Figs. 7 and 8 and Methods).

To test the method’s capability for ‘high-resolution’ cell purification (Fig. 1), we created a series of synthetic mixtures, each containing DEGs in one or more cell types. These DEGs were simulated to include overlapping block-like patterns, reminiscent of those seen in real tissues28–30, and non-linear geometries, all of which would have been difficult to ascertain by previous computational techniques. Remarkably, the method recovered expected DEG patterns in all tested cases, including an obscured target (‘bullseye’) (Fig. 4b–d and Supplementary Fig. 9). Moreover, unlike group mode (Fig. 1), the resulting high-resolution profiles were amenable to standard methods for unsupervised analysis (for example, Fig. 4c).

Using modeled tumor admixtures, we next evaluated the analytical performance of the method across several parameters, including cell type abundance and the magnitude of differential expression. First, simulated DEGs were ‘spiked’ into CD8 T cell transcriptomes to create two phenotypic classes. These CD8 GEPs were then randomly admixed in silico with three other immune subsets in modeled tumors, and a colon cancer cell line was included to simulate 50% unknown content (Fig. 4e, left). Following high-resolution purification, cell-type-specific transcriptomes were grouped into defined DEG classes. Across a broad range of cell spike-in levels and expression fold changes, previously defined DEGs were recovered in CD8 T cells with high sensitivity and specificity (Fig. 4e, right). We observed similar performance in a second experiment, where we simulated melanoma tumors using pooled scRNA-seq data10 and assessed the above parameters in relation to cohort size (Supplementary Fig. 10).

High-resolution profiling of diverse tumor subpopulations. Diffuse large B cell lymphoma (DLBCL) can be classified into two major molecular subtypes based on differences in B cell differentiation states: germinal center-like (GCB) and activated B cell-like (ABC) DLBCL34. Using GEPs of 150 DLBCL lymph node biopsies with previously annotated cell-of-origin subtypes34, we asked whether high-resolution profiling of ten major leukocyte subsets could correctly attribute known cell-of-origin differences to B cells. Although our approach was blinded to class labels, we identified DLBCL subtype-specific expression differences in malignant B cells that were (1) highly consistent with those of normal GC and activated B cells and (2) about ninefold more significant, on average, than in bulk DLBCL tumors (Supplementary Fig. 11a–c). Notably, we obtained similar results when repeating this analysis using 10X Chromium-derived signature matrices derived from either peripheral blood or FL tumors, demonstrating the generalizability of our approach (Supplementary Fig. 11d,e).

We then compared our results with two alternative methods: (1) a common strategy for assigning bulk tissue expression patterns...
to individual cell types based on correlations with cell abundance\(^2\); and (2) a previously described technique for imputing cell-type-specific DEGs when phenotypic classes and cell type frequencies are known\(^2\). In both cases, CIBERSORTx exhibited superior performance in relation to both cell type specificity and the number of detectable DEGs at a given significance threshold (Supplementary Figs. 12 and 13a,b).

FL is the most common indolent non-Hodgkin lymphoma, and \textit{CREBBP} mutations in FL tumors are associated with reduced antigen presentation in B cells\(^3\). Since we originally discovered this association using FACS-purified FL B cells\(^4\), we asked whether high-resolution purification could recapitulate this result starting from bulk tumor GEPs and paired tumor genotypes (Fig. 5a). Indeed, after tumors were stratified by \textit{CREBBP} mutation status (Supplementary Table 3), previously described signatures were detectable in digitally sorted B cell GEPs, including loss of MHC II expression in \textit{CREBBP}-mutant tumors (Fig. 5b,c). Notably, this result was reproducible across microarray and 10x Chromium-derived signature matrices covering leukocyte subsets derived from distinct biological sources (Fig. 5b,c and Supplementary Fig. 14a,b). Moreover, as observed for DLBCL (Supplementary Fig. 11), the majority of \textit{CREBBP} mutation-associated genes did not correlate with B cell abundance, hindering their discovery in bulk tissues without deconvolution (Supplementary Fig. 14c).

To extend our assessment to solid tumors, we obtained surgically resected primary NSCLC tumor biopsies (\(n=26\) patients), and for each tumor, generated RNA-seq libraries of four major subpopulations purified by FACS: epithelial/cancer (EpCAM\(^+\)) and stromal (CD10\(^+\) or CD31\(^+\)) subpopulations imputed from bulk RNA-seq profiles of 26 NSCLC tumors (g). Genes that were not predicted to be expressed or that were removed by adaptive noise filtration are colored navy blue.

**Fig. 3** Purification of representative cell-type-specific transcriptome profiles from a group of specimens. a, Approach for in silico purification and validation of group-mode cell-type-specific GEPs. b–d, Scatter plots comparing genome-wide expression levels of mathematically purified (x axis) and FACS-purified (y axis) B cells and CD8 T cells from FL lymph nodes before (b) after (c) applying an adaptive noise filter based on the transcriptome-wide distribution of coefficient of variation (c.v.) values for each cell type (c). Concordance was determined by applying Pearson correlation (\(r\)), Spearman correlation (\(\rho\)) and linear regression (diagonal line) to genes with detectable expression on both platforms. Scatter plots in c show the predicted expression level of each gene in \(b\) (y axis) as a function of its uncertainty, as captured by the geometric c.v. (x axis). e, Analysis of the impact of sample size on group-mode gene expression purification for three FL tumor cell subsets, as assessed by Spearman correlation against corresponding FACS-purified GEPs (‘ground truth’) in log space. For each sample size, tumors were subsampled without replacement from a larger cohort (\(n=302\)) 10 times, and the results are shown with and without adaptive noise filtration. Data are presented as boxplots (center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range; points, outliers). f, g, Heat map comparing imputed and ground truth expression profiles for three FL immune subsets, with LM22 genes as rows and immune cell types as columns (f), and for immune (CD45\(^+\)), epithelial/cancer (EpCAM\(^+\)) and stromal (CD10\(^+\) or CD31\(^+\)) subpopulations imputed from bulk RNA-seq profiles of 26 NSCLC tumors (g). Genes that were not predicted to be expressed or that were removed by adaptive noise filtration are colored navy blue.
outperformed other methods \(^{35}\) for purifying GEPs of epithelial cells from bulk tumors while also enabling the digital purification of more cell types (Supplementary Fig. 13c–e).

We applied the same signature matrix to resolve epithelial/cancer, hematopoietic, and fibroblast GEPs from bulk RNA-seq profiles of 518 lung adenocarcinoma (LUAD) tumors, 504 lung squamous cell carcinoma (LUSC) tumors and 110 adjacent normal tissues from TCGA \(^{40,41}\) (Fig. 5d). Using \(t\)-distributed stochastic neighbor embedding (\(t\)-SNE) to visualize the resulting GEPs, we identified striking patterns of histology-specific gene expression for most cell types, including distinct phenotypic shifts in cancer-associated fibroblasts (CAFs) (Fig. 5e). Histological differences were far less pronounced in tumor-associated endothelial cells, and adjacent normal tissues clustered together regardless of histology.

We compared these results with bulk RNA-seq profiles of FACSpurified NSCLC cell subpopulations from 21 patients with LUAD or LUSC. We observed similar clustering tendencies at the whole-transcriptome level and strong concordance in relation to patterns of cell-type-specific differential expression between histological subtypes (Fig. 5e,f, Supplementary Table 4 and Supplementary Note 1). Our results were further corroborated by histology-specific DEGs and tumor-specific DEGs identified from a recently published scRNA-seq atlas of NSCLC tumors and adjacent normal tissues \(^{42}\) (Supplementary Fig. 15 and Supplementary Table 4).

Applications of CIBERSORTx to melanoma. We implemented the set of CIBERSORTx techniques into a comprehensive toolkit (http://cibersortx.stanford.edu). We then explored three potential...
Fig. 5 | High-resolution expression profiling of bulk tumor biopsies. a–c, Analysis of CREBBP mutation-associated expression changes in B cells from FL tumors. a, Schema outlining the application of high-resolution purification to identify CREBBP mutation-associated DEGs in FL B cells. b, Heat map confirming loss of MHC class II expression in CREBBP-mutant FL B cell GEPs inferred by CIBERSORTx. Expression values were median-centered prior to plotting. c, Analysis of published gene sets associated with lower (left) or higher (right) B cell expression in CREBBP-mutant FL tumors. Scatter plots show the corresponding log expression of each gene in digitally sorted B cell GEPs after median centering and averaging by CREBBP mutation status. Group comparisons in c were assessed by a two-sided Wilcoxon signed-rank test. Data are presented as means ± s.d. WT, wildtype (n = 14). d–f, High-resolution expression profiling of tumor cell subpopulations from NSCLC tumors. d, Schema for profiling and validating expression signatures of epithelial and cancer cells (Epith., EpCAM+), immune cells (Imm., CD45+) fibroblasts (Fib., CD10+) and endothelial cells (Endo., CD31+) in 1,022 NSCLC tumors and 110 adjacent normal GEPs from TCGA. e, Left: t-SNE plots showing population-specific transcriptional diversity imputed from 1,132 NSCLC GEPs, color-coded to denote tumor histological subtype (LUAD versus LUSC) and adjacent normal tissues. Plots were created with perplexity set to 10. Right: PCA plots of 21 GEPs from corresponding FACs-purified populations, color-coded by tumor histological subtype. Histological differences are highlighted by ovals. f, Heat maps showing DEGs identified in epithelial/cancer, immune and fibroblast populations identified in NSCLC tumors from TCGA (left, n = 1,022 tumor samples) and RNA-seq profiles of corresponding FACs-purified populations from 21 patients with NSCLC of subtype LUAD or LUSC (right; Supplementary Table 1). The same genes are shown in both heat maps and are ordered identically. For clarity, a maximum of 300 over- and underexpressed genes are shown for each cell type (all DEGs are provided in Supplementary Table 4). Median centering was applied to each cell population separately. To quantify DEG concordance between CIBERSORTX and the bulk sorted validation profiles in f, we used the Monte Carlo strategy described in Supplementary Note 1.

applications of CIBERSORTX for characterizing cellular heterogeneity in resected tumor biopsies from patients with melanoma. The following advantages were applied in turn: high-resolution expression purification (Fig. 6a,b), group-mode expression purification (Fig. 6c) and enumeration of cell composition across diverse platforms using single-cell reference profiles (Fig. 6d–f).

Oncogenic BRAF mutations occur in over half of melanomas and can be inhibited by approved targeted therapies, whereas NRAS mutations occur in approximately half of non-BRAF mutant melanoma tumors but lack such therapies. Understanding how key mutations influence cellular states could potentially lead to new treatment strategies. Using single-cell reference profiles from melanomas to build a signature matrix, we applied high-resolution expression purification to dissect eight major cell types from the transcriptomes of 342 bulk melanoma tumors profiled by TCGA. Within digitally purified cell subsets, we discovered many significant DEGs within malignant cells and CAFs that distinguish melanomas according to BRAF or NRAS mutation status. We verified these findings using scRNA-seq data from primary melanomas where mutation data were available, allowing us to confirm GEPs associated with BRAF and NRAS genotypes within individual malignant cells and/or CAFs. We next used CIBERSORTX to examine expression changes that characterize the exhaustion of CD8 T cells
phenotype. Using LM22, which is derived from healthy peripheral blood leukocytes, we enumerated immune composition in FF melanomas profiled by TCGA. We then performed group-mode expression purification to impute a representative CD8 TIL GEP. By rank-ordering the estimated CD8 TIL GEP against a baseline reference profile of normal peripheral blood CD8 T cells, we confirmed the expression of key exhaustion markers in the inferred CD8 TIL GEP (Fig. 6c). In addition, CD8 TIL-specific genes were consistent with those observed for CD8 TILs isolated from melanomas by scRNA-seq and by FACS (Fig. 6c). Similar results were obtained when repeating the analysis on FFPE tumors (Fig. 6c and Supplementary Fig. 17).
The most effective regimens for metastatic melanoma currently employ checkpoint blockade targeting PD-1 and/or CTLA4 expression on exhausted T cells\(^{47}\). Although a subset of patients achieve durable anti-tumor T cell responses, clinical outcomes remain heterogeneous, and effective predictive biomarkers are lacking\(^{48}\). CD8 TILs expressing high levels of PDCD1 (encoding PD-1) or CTLA4 are key targets of these therapies\(^{49,50}\), suggesting that CD8 TILs expressing both markers might correlate with response, as was recently shown in patients with melanoma receiving PD-1 blockade\(^{51}\). To test this hypothesis, we used single-cell reference profiles of melanoma tumors to build a signature matrix containing \(\text{PDCD1}^+\text{CTLA4}^+\) CD8 T cells along with eight other major tumor cell types (Fig. 6d and Supplementary Figs. 3b and 18a,b). We then applied the signature matrix to interrogate three publicly available melanoma expression datasets (Fig. 6d). These included bulk expression data of FFPE and FF melanoma tumors that were profiled by RNA-seq or NanoString\(^{53,55}\). In support of our hypothesis, imputed levels of \(\text{PDCD1}^+\text{CTLA4}^+\) CD8 T cells were significantly associated with response in all three studies (\(P<0.05\); Fig. 6e). Moreover, the detection of these cells stratified overall survival in this meta-analysis, separated survival curves in individual datasets, and showed a more robust association with survival and response than key marker genes and other cell types (Fig. 6f and Supplementary Fig. 18c–f).

**Discussion**

In this study, we present CIBERSORTx as a new platform for in silico tissue dissection. Key features that distinguish it from previous work include dedicated normalization schemes to suppress cross-platform variation and improved approaches for separating RNA admixtures into cell-type-specific expression profiles. In our analysis of peripheral blood, pancreatic islet specimens and nearly 2,300 malignant tumors, 444 of which were profiled in this work, we found that CIBERSORTx delivers accurate portraits of human tissue heterogeneity using expression profiles derived from disparate sources. Efforts to define comprehensive cell aliases are now underway\(^{54,55}\).

Given the rapid pace of data generation coupled with emerging techniques to combine scRNA-seq datasets\(^{56,57}\), methods to broadly apply single-cell reference maps will become increasingly important, especially in settings where tissue is limited, fixed or challenging to disaggregate into intact single cells. In our analysis of neoplastic and healthy tissues, we demonstrated that single-cell reference profiles can enable detailed interrogation of tissue composition and that inter-subject heterogeneity is not a major factor influencing results. While significant differences in performance between reference signatures derived from bulk populations and those derived from scRNA-seq data were not observed, the latter have several advantages for CIBERSORTx (Supplementary Note 2). These include (1) the ability to customize signature matrices for nearly any tissue type without the need for complicated antibody panels or cell sorting schemes and (2) the ability to study poorly understood or unknown transcriptional states at scale.

CIBERSORTx also enables robust molecular profiling of cell subset GEPs from complex tissues independently of expression profiling platform or tissue preservation state. By incorporating two techniques for expression analysis, we showed that CIBERSORTx outperforms previous methods to facilitate rapid assessment of cell type GEPs when phenotypic categories are known, and high-resolution profiling of expression variation when additional detail is desired. With these features, we anticipate that CIBERSORTx will improve our understanding of heterotypic interactions within complex tissues, including tumor microenvironments, with implications for informing diagnostic and therapeutic approaches that rely on targeting specific cell types.

CIBERSORTx currently requires multiple bulk tissue samples for expression purification. Although further developments are needed to better accommodate smaller sample sizes (for example, <15), we expect expression purification to be feasible in many situations, particularly given the abundance of publicly available tissue GEPs and the affordability of bulk RNA-seq. Second, while the fidelity of cell reference profiles remains an important consideration for deconvolution applications\(^{53,58}\), scRNA-seq can mitigate this issue, as shown in this work. Finally, like its predecessor\(^{59}\), we hypothesize that the algorithmic principles underlying CIBERSORTx are likely to generalize to other species and genomic data types. Future studies will be needed to formally demonstrate these possibilities.

In summary, CIBERSORTx represents a broadly applicable framework for decoding cellular heterogeneity in complex tissues. This strategy can be used to ‘digitally gate’ cell subsets of interest from single-cell transcriptomes, profile the identities and expression patterns of these cells in cohorts of bulk tissue GEPs (for example, fixed specimens from clinical trials), and systematically determine their associations with diverse metadata, including genomic features and clinical outcomes. CIBERSORTx should therefore have utility for increasing the statistical power for biological discovery. Given the versatility of the approach and its potential for seamless integration with other techniques, we envision that digital cytometry will enhance the analysis of multicellular systems in humans, mice and other metazoans.

**Online content**

Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/s41587-019-0114-2.

Received: 15 December 2017; Accepted: 26 March 2019; Published online: 6 May 2019

**References**

1. Wagner, A., Regev, A. & Yosef, N. Revealing the vectors of cellular identity with single-cell genomics. *Nat. Biotech.* 34, 1145–1160 (2016).
2. Shen-Orr, S. S. & Gaujoux, R. Computational deconvolution: extracting cell type-specific information from heterogeneous samples. *Curr. Opin. Immunol.* 25, 571–578 (2013).
3. Newman, A. M. & Alizadeh, A. A. High-throughput genomic profiling of tumor-infiltrating leukocytes. *Curr. Opin. Immunol.* 41, 77–84 (2016).
4. Aran, D., Hu, Z. & Butte, A. I. Cell: digitally portraying the tissue cellular heterogeneity landscape. *Genome Biol.* 18, 220 (2017).
5. Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E. & Géller, D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. *eLife* 6, e26476 (2017).
6. Quon, G. et al. Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction. *Genome Med.* 5, 29 (2013).
7. Angelova, M. et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. *Genome Biol.* 16, 64 (2015).
8. Becth, E. et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. *Genome Biol.* 17, 218 (2016).
9. Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. *Cell* 171, 1611–1624 (2017).
10. Tirosch, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* 352, 189–196 (2016).
11. Baron, M., et al. A single-cell transcriptomic map of the human and mouse pancreas reveals intra- and inter-cellular population structure. *Cell Syst.* 3, 346–360.e4 (2016).
12. Lappalainen, T. & Greally, J. M. Associating cellular epigenetic models with human phenotypes. *Nat. Rev. Genet.* 18, 441–451 (2017).
13. He, Z. et al. Comprehensive transcriptome analysis of neocortical human phenotypes. *Nat. Neurosci.* 20, 886–895 (2017).
14. Scheller, M. et al. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. *Nat. Commun.* 8, 2032 (2017).
15. Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. *Nat. Methods* 12, 453–457 (2015).
16. Ziegenhain, C. et al. Comparative analysis of single-cell RNA sequencing methods. Mol. Cell 65, 631–643.e634 (2017).
17. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).
18. Dvinge, H. et al. Sample processing obscures cancer-specific alterations in leukemic transcripts. Proc. Natl Acad. Sci. USA 111, 16802–16807 (2014).
19. Kadić, E., Moniz, R. J., Hoo, Y., Chi, A. & Kariv, I. Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determined by multiparametric single cell mass cytometry analysis. BMC Immunol. 18, 6 (2017).
20. Chen, P.-L., et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827–837 (2016).
21. Segerstolpe, A. et al. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab. 24, 593–607 (2016).
22. Gajoures, R. & Seoighe, C. CellMix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics 29, 2211–2212 (2013).
23. Liechner, D. A., Huang, K. & Parvin, J. D. MMAP: microarray microdissection with analysis of differences is a computational tool for deconvoluting cell type-specific contributions from tissue samples. Bioinformatics 30, 682–689 (2014).
24. Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168–1178 (2015).
25. Shen, R. S. et al. Cell type-specific gene expression differences in complex tissues. Nat. Methods 7, 287–289 (2010).
26. Zhong, Y., Wan, Y., Wang, P., Chow, L. M. & Liu, Z. Digital sorting of complex tissues for cell type-specific gene expression profiles. BMC Bioinformatics 14, 89 (2013).
27. Zachkerman, N. S., Noam, Y., Goldsmith, A. J. & Lee, P. P. A self-directed method for cell-type identification and separation of gene expression microarrays. PLoS Comput. Biol. 9, e1003189 (2013).
28. Onuchic, V. et al. Epigenomic deconvolution of breast tumors reveals metabolic coupling between constituent cell types. Cell Rep. 17, 2075–2086 (2016).
29. Green, M. R. et al. Mutations in early follicular lymphoma progenitors are identified by gene expression profiling. Nature 403, 503–511 (2000).
30. Golub, T. R. et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537 (1999).
31. Bied, A. H. et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 450, 715–725 (2007).
32. Lenz, G. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313–2323 (2008).
33. Whitney, A. R. et al. Individuality and variation in gene expression patterns in human blood. Proc. Natl Acad. Sci. USA 100, 1896–1901 (2003).
34. Jiang, Y. et al. CREBBP inactivation promotes the development of HDAC3-dependent lymphomas. Cancer Discov. 7, 38–53 (2017).
35. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
36. Cancer Genome Atlas Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
37. Lambrecht, B., et al. Phenotype modeling of stem cells in the lung tumor microenvironment. Nat. Med. 24, 1277–1289 (2018).
38. Davies, H. et al. Mutations of the Braf gene in human cancer. Nature 417, 949–954 (2002).
39. Abkani, R., et al. Genomic classification of cutaneous melanoma. Cell 161, 661–667 (2015).
40. Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135–2147 (2005).
41. Scher, H. et al. Metastasis. J. Clin. Oncol. 33, 1974–1992 (2015).
42. Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: coinhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016).
43. Baitzsch, L. et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350–2360 (2011).
44. Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
45. Redman, J. M., Gribben, G. T. & Atkins, M. B. Advances in immunotherapy for melanoma. BMC Med. 14, 20 (2016).
46. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
47. Kwisthorg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6, 234ra128 (2014).
48. Daud, A. I. et al. Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452 (2016).
49. Nathanson, T. et al. Somatic mutations and neoeptope homology in melanomas treated with CTLA-4 blockade. Cancer Immunol. Res. 5, 84–91 (2017).
50. Cao, J. et al. Comprehensive single-cell transcriptional profiling of a human melanoma xenograft. Cell 168, 1681–1696 (2016).
51. Butler, A., Hofmann, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411 (2018).
52. Haghverdi, L., Lun, A. T. L., Morgan, M. D. & Marioni, J. C. Batch effects in single-cell RNA sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol. 36, 421 (2018).
53. Chakravarty, A. et al. Pan-cancer deconvolution of tumour composition using DNA methylation. Nat. Commun. 9, 3220 (2018).
54. Corces, M. R., et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat. Genet. 48, 1193–1203 (2016).
55. Abbas, A. R. et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 6, 319–331 (2005).
56. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression data. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

Acknowledgements

We are grateful to R. Levy, S.K. Plevritis, B. Chen, B. Nabet and M. Matusiak for assistance with this study. This work was supported by grants from the National Cancer Institute (A.M.N., R00CA187192; A.A.A., U01CA194389; A.A.A. and M.D., R01CA188298; S.K.P., U01CA154969), the Stinehart-Reed foundation (A.M.N., A.A.A.), the Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program (IIP) (A.M.N.), the Virginia and D.K. Ludwig Fund for Cancer Research (A.M.N., A.A.A.), the US Department of Defense (A.M.N., W81XWH-12-1-0498), the Shanahan and Bronzini Family Funds (A.A.A.), anonymous donors (A.A.A., A.M.N.), the Y Foundation for Cancer Research (A.A.A.), the Leukemia and Lymphoma Society (A.A.A.), the Damon Runyon Cancer Research Foundation (A.A.A.) and the American Society of Hematology (A.A.A.).

Author contributions

A.M.N. and A.A.A. conceived of CIBERSORTx, developed strategies for related experiments, and wrote the paper with input from C.L.I., C.B.S., A.J.G., M.S.E. and M.D. A.M.N. developed and implemented CIBERSORTx and analyzed the data. C.L.I. and C.B.S. implemented web infrastructure. C.B.S. assisted with CIBERSORTx's software development and validation experiments. A.J.G. assisted in the development of CIBERSORTx. A.A.A. and M.S.K. performed flow cytometry and single-cell profiling. F.S. performed targeted DNA sequencing of FL tumor specimens. B.A.L. assisted with validation studies. D.S. assisted with data acquisition. M.D. assisted in the collection and expression profiling of patient specimens. All authors commented on the manuscript at all stages.

Competing interests

A.M.N. has patent filings related to expression deconvolution and cancer biomarkers and has served as a consultant for Roche, Merck and CiberMed. A.A.A. has patent filings related to expression deconvolution and cancer biomarkers and has served as a consultant or advisor for Roche, Genentech, Janssen, CiberMed, Pharmacycila, Gilead and Celgene. M.D. has patent filings related to cancer biomarkers and has served as a consultant for Roche, Novartis, CiberMed and Quantec Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41587-019-0114-2.

Reprints and permissions information is available at www.nature.com/reprints.

Correspondence and requests for materials should be addressed to A.M.N. or A.A.A.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Methods

Additional details are described in Supplementary Note 1.

Human subjects. All patient samples in this study were collected with informed consent for research use and were approved by the Stanford Institutional Review Board in accordance with the Declaration of Helsinki. For a patient with metastatic NSCLC treated with an immune checkpoint inhibitor (Pembrolizumab, Merck), peripheral blood was obtained on the first day of treatment prior to infusion (Fig. 2c; NCT00349830 and NCT02955758). Fresh tumor biopsies from patients with early stage NSCLC were obtained during routine primary surgical resection (Figs. 3g and 5 and Supplementary Fig. 13e–f). Fresh or frozen surgical biopsies of FL tumors were obtained from previously untreated patients with FL enrolled in a phase III clinical trial (NCT0017295; ref. 63), as well as from patients seen as part of the Stanford University Lung Amyloidosis Program Project (NCT00398177; Figs. 3b–f and 5a–c, and Supplementary Figs. 6a–c and 16). Whole blood samples from 12 healthy adult donors were obtained from the Stanford Blood Center (28e and Supplementary Figs. 1d,3,1 and 2a,d).

External datasets. Full details of each dataset, including data type, sample type, source and normalization approach, are available in Supplementary Table 1. Briefly, next generation sequencing datasets were downloaded and analyzed using the authors’ normalization settings unless otherwise specified; these consisted of transcripts per million (TPM), reads per kilobase of transcript per million (RPKM) or fragments per kilobase of transcript per million (FPKM) space. For analyses in log2 space, we added 1 to expression values prior to log2 adjustment. Using the authors’ normalization settings unless otherwise specified; these consisted of transcripts per million (TPM), reads per kilobase of transcript per million (RPKM) or fragments per kilobase of transcript per million (FPKM) space. For analyses in log2 space, we added 1 to expression values prior to log2 adjustment. Affymetrix microarrays were summarized as described in ‘Gene expression profiling – Single-cell RNA-seq’. Table 1, using the robust multi-array averaging (RMA) method in cases where bulk tissues and ground truth cell subsets were profiled on the same Affymetrix platform, and otherwise using MAS5 normalization. NanoString nCounter data were downloaded from the supplement of Chen et al. and analyzed with batch correction in non-log linear space, but without any additional pre-processing.

Two publicly available PBMC datasets from healthy donors profiled by Chromium v2 (5’ and 3’ kits) were downloaded (Supplementary Table 1) and preprocessed as described in ‘Gene expression profiling – Single-cell RNA-seq’ (Supplementary Note 1), with the following minor modifications. During quality control, we excluded cells with >5,000 expressed genes for 5’ PBMCs, >4,000 expressed genes for 3’ PBMCs and <200 expressed genes for both datasets. Seurat ‘FindClusters’ was applied on the first 20 principal components, with the resolution parameter set to 0.6. Cell labels were assigned as described above. In addition, myeloid cells were defined by high CD14 expression, megakaryocytes by high PBPD expression and dendritic cells by high FCER1A expression.

For the 3’ FL signature matrix in Supplementary Figs. 1d and 1a,b, publicly available 10x Chromium v2 scRNA-seq data (3’ kits) were downloaded (Supplementary Table 1) and preprocessed as described for the 10x PBMC signature matrices above, but with the following differences. Seurat ‘FindClusters’ was applied on the first ten principal components, with the resolution parameter set to 0.6. Cell labels were assigned based on the following canonical marker genes: (MS1A1 = B cells; CD3E, CD8A and CD8B = CD8 T cells; CD3E and CD4 = CD4 T cells).

Single-cell signature matrix construction. Expression data from input datasets (Supplementary Table 1) were summarized as described above. Given the variability in cell type representation and the inherent noise in scRNA-seq data, several techniques have been developed to address stochastic dropout, impute cell-level scaling factors, and model technical and biological noise components in single-cell differential expression analysis37–41. Although these were useful for defining single cell phenotypes, we did not observe any significant gains in deconvolution performance when applying such techniques after cell labels were assigned based on canonical marker genes (MS1A1 = B cells; CD3E, CD8A and CD8B = CD8 T cells; CD3E and CD4 = CD4 T cells).

Single-cell signature matrix construction. Expression data from input datasets (Supplementary Table 1) were summarized as described above. Given the variability in cell type representation and the inherent noise in scRNA-seq data, several techniques have been developed to address stochastic dropout, impute cell-level scaling factors, and model technical and biological noise components in single-cell differential expression analysis37–41. Although these were useful for defining single cell phenotypes, we did not observe any significant gains in deconvolution performance when applying such techniques after cell labels were assigned based on canonical marker genes (MS1A1 = B cells; CD3E, CD8A and CD8B = CD8 T cells; CD3E and CD4 = CD4 T cells).

All single cell-derived signature matrices are available in Supplementary Table 2.

Overview of CIBERSORT’s analytical framework. Introduction. A number of methods have been proposed to infer cell type abundance, cell-type-specific GEPs or both from bulk tissue expression profiles42–44. These methods generally assume that biological mixture samples can be modeled as a system of linear equations, where a single mixture transcriptome m with n genes is represented as the product of H and f, where H represents an n × k cell type expression matrix consisting of expression profiles for the same n genes across k distinct cell types, and f represents a vector of size c, consisting of cell type mixing proportions.

To infer cell type abundance using this linear model within CIBERSORT, let M be an n × k matrix with n genes and k mixture GEPs, let matrix B be a subset H containing discriminatory marker genes for each of the c cell subsets (signature or basis matrix45–47) and let M’ be the subset of M that contains the same marker genes as B. Given M’ and B, the following equation can then be used to impute f, a c × k fractional abundance matrix with columns [f1, ..., fc]T:

\[ f \times B = M' \times f, \quad 1 \leq k \leq c \]

where f1 ≥ 0 for all i, the system is overdetermined (that is, n > c), and expression data in M’ and B are represented in non-log linear space48. (Note that M’ and M, denote row i and column j of matrix M, respectively.) Many methods either normalize f or impose an additional constraint on f such that for each mixture sample, the inferred mixing coefficients sum to one, allowing f to be directly interpreted as cell type proportions (with respect to the cell subsets in B). We previously introduced CIBERSORT as a method to estimate F using an implementation of a support vector regression, a machine learning technique that is robust to noise, unknown mixture content, and collinearity among cell type references48. CIBERSORT was used to impute F in this work, and within this imputation workflow, the batch correction scheme described below was used for all cross-platform analyses unless stated otherwise (Supplementary Table 1).

Group-mode expression purification. The fractional abundance matrix F can be determined for the bulk GEP matrix M, either through expression deconvolution as described above48 or with prior empirical knowledge of the compositional representation of cell types within the bulk specimen (for example, by an automated hematologic analyzer or by flow cytometry)49,50. Once F is determined for a given M, a representative imputed GEP for each cell type in F can be estimated by solving the following system of linear equations:

\[ H_i \times F = M_i, \quad 1 \leq i \leq n \]

where H is an n × c expression matrix of n genes and c cell types, Hi ≥ 0 for all i, j, and F is defined as above with the constraint that relative cell fractions sum one for each mixture sample. Like equation (1) above, the system should be overdetermined (k > c), with a greater difference between k and c generally leading to improved GEP estimation (Fig. 3e and Supplementary Fig. 6). To ensure biologically realistic estimates of gene expression, we employ non-negative least squares regression (NNLS), an optimization framework to solve the least squares problem with non-negativity constraints. Although NNLS is robust on simple mixtures and toy examples, its performance on more complex mixtures inherent within real tissue samples can be affected by noise, imprecision and missing data in the linear system51. We therefore developed a series of data normalization and filtering techniques to help mitigate these issues (Fig. 3b–d; see ‘Imputation of group-mode expression profiles’ in Supplementary Note 1).

Rationale for high-resolution expression purification. Despite the utility of equation (2) for imputing cell-type-specific gene expression from bulk tissues (for example, in silico purifications in Fig. 3), it can only estimate a single representative GEP for each cell type. Therefore, to explore cell-type-specific DEGs between more than one condition of interest, cell type transcriptomes must be re-generated for each condition (for example, responders versus non-responders to a given therapy, early versus advanced stage disease, and so on). To more broadly address this issue, we extended the model in equation (2) within a new method for high-resolution in silico cell purification.

Our approach decomposes a matrix of bulk tissue GEPs (M) into c gene expression matrices of equal size, one for each cell subset in the cell fraction matrix F. Unlike previous approaches33–35–37, this method is entirely agnostic to phenotypic class structure and can be formulated as a unique non-negative matrix factorization (NMF) problem with partial observations. Let M and F be defined as above (n × k and c × k matrices, respectively), and assume the latter is estimated by CIBERSORT15. Then, for each gene i, we seek to determine an expression matrix Gi defined here as a k × c expression matrix of k mixture samples by c cell types. Fixing M and F to solve for Gi yields the following constrained matrix decomposition problem:

\[ \text{diag}(G_{i1} \times F) = M_i, \quad 1 \leq i \leq n \]

where \( \text{diag}(G) \) is the diagonal matrix of G and \( \text{diag}(A) \) is the diagonal matrix of A.
where $G_{ijk} \geq 0$ for all $i, j, k$. Unlike the linear systems in equations (1) and (2), there are no closed-form solutions for $G$, which is a three-dimensional $n \times k \times c$ matrix, and existing numerical techniques are unlikely to yield biologically plausible estimates without additional constraints (for example, regularization). Since conventional approaches for non-negative matrix factorization \(^7\) are not directly applicable to equation (3), we developed a heuristic algorithm to estimate $G$, depicted schematically in Supplementary Fig. 7 and described below.

Our approach for inferring $G$ makes two distinct assumptions that improve the tractability of the problem while generating biologically plausible solutions. First, we assume that each gene can be analyzed independently. Although ignoring gene-gene covariance relationships will probably impact the resolving power for some genes, we found this assumption to be effective in practice (for example, gene-gene covariance relationships will probably impact the resolving power for some tractability of the problem while generating biologically plausible solutions. First, we developed a heuristic algorithm to estimate $G$, denoted $\hat{M}$, and a signature matrix comprised of cell type reference profiles (denoted $\hat{B}$) while preserving biological signal. This is because, unlike technical batches of the same sample type, both biological differences and technical batches are inherently conflated in the setting of deconvolution. By leveraging technical dropout cross-platform normalization in bulk GEP and scRNA-seq data are not directly applicable to this problem.\(^8\)\(^-\)\(^10\), we developed a new approach for cross-platform deconvolution (Supplementary Fig. 1). By exploiting the fact that $M$ can be modeled as a linear combination of $B$ and $\hat{B}$, and by estimating $M$ from $B$ (denoted $M^*$), batch correction can be directly applied to $M$ and $M^*$ to correct for expression purification, allowing the down-weighting of genes whose expression levels are low or absent from the collection of cell types in the signature matrix.

For high-resolution expression purification. Given these foundational assumptions, along with a mixture GEP matrix $M$ and cell type fractional abundance matrix $F$, we developed a heuristic algorithm for high-resolution purification. An overview of this heuristic is outlined in the text below, with a corresponding graphical summary in Supplementary Figure 7 and additional algorithmic details provided in Supplementary Note 1:

1. For a given gene $i$, estimate whether the gene is significantly expressed by at least one cell type (Supplementary Fig. 7c, step 1). If so, proceed to step 2. If not, proceed to the next gene.

2. Sort the gene's corresponding bulk mixture vector $M_i$ into ascending order (Supplementary Fig. 7c, step 2). Any cell-type-specific DEGs with detectable signal in $M_i$ will influence this ordering, and the most prominent DEGs are likely to skew to one side of the distribution (for example, Supplementary Fig. 8b).

3. Split the vector into two groups using a sliding window strategy (Supplementary Figure 7c, step 3). For each group, compute cell-type-specific gene expression coefficients for $c$ cell types (denoted $g$, for group 1 and $g^*$ for group 2) (Supplementary Figure 7c, step 3, left). Find the $g, g^*$ pair that best explains $M_i$ (Supplementary Figure 7c, step 3, right).

4. Perform significance testing to determine whether the gene is statistically different between $g$ and $g^*$, for each cell type (Supplementary Figure 7c, step 4).

5. Refine estimates of $g$ and $g^*$ based on the significance of their differential expression (Supplementary Figure 7c, step 5).

6. Impute smooth expression values for each cell type using a sliding window strategy, and store as matrix $G$ (Supplementary Figure 7c, step 6).

7. Adjust smooth expression vectors in $G$ to maximize their agreement with $g$ and $g^*$ (Supplementary Figure 7c, step 7).

8. Restore the original sample ordering of $g$ based on sample ordering in $M$ (Supplementary Figure 7c, step 8).

9. Repeat steps 1 through 8 for all genes.

Within this framework, cell-type-specific gene expression vectors are imputed using NNLS (detailed in Supplementary Note 1). In order to capture variation in expression across $M_i$, equation (2) is iteratively solved on subsets of mixture samples grouped by similar expression values. The size of each subset is governed by a sliding window of length $w$. In order to satisfy NNLS constraints and to avoid overlapping phenotypic classes, $w$ is bounded by the interval $c < w < (k/2)$, where $c$ denotes the number of cell types and $k$ denotes the number of samples. We observed favorable performance of this approach across a broad range of $w$ values. Nevertheless, given the marginal gains observed with increasingly large $w$ values within our saturation analysis of group-mode expression purification (Fig. 2e and Supplementary Fig. 6), we set $w$ to four–fivefold greater than $c$, which balances performance with practical considerations based on our empirical observations.

To address potential instability in the linear system and to infer expression coefficients with robust standard errors and confidence intervals, NNLS is run using bootstrapping. Additional details are provided in Supplementary Note 1.

Cross-platform deconvolution. While several prior studies have applied CIBERSORT to RNA-seq, including to reference phenotypes derived from single-cell transcriptome profiling,\(^11\)\(^-\)\(^13\), our original description of CIBERSORT did not explicitly handle technical variation between the signature matrix and bulk mixture profiles. To the best of our knowledge, there is no previously described approach that can be applied to eliminate technical variation between mixture sample expression profiles (denoted $M$) and a signature matrix comprised of cell type reference profiles (denoted $B$) while preserving biological signal. This is because, unlike technical batches of the same sample type, both biological differences and technical batches are inherently conflated in the setting of deconvolution. By leveraging technical dropout cross-platform normalization in bulk GEP and scRNA-seq data are not directly applicable to this problem.\(^8\)\(^-\)\(^10\), we developed a new approach for cross-platform deconvolution (Supplementary Fig. 1). By exploiting the fact that $M$ can be modeled as a linear combination of $B$ and $\hat{B}$, and by estimating $M$ from $B$ (denoted $M^*$), batch correction can be directly applied to $M$ and $M^*$ to correct for expression purification across distinct platforms and tissue storage types (for example, FF versus FFPE). A decision tree to guide users in selecting the most appropriate strategy is provided in Supplementary Figure 1a. A comprehensive description of our approach is provided in Supplementary Note 1.

B-mode. Bulk-mixture batch correction (B-mode) removes technical differences between a signature matrix derived from bulk sorted reference profiles (for example, bulk RNA-seq or microarrays) and an input set of mixture samples (Supplementary Fig. 1c). The technique can also be applied to signature matrices derived from droplet-based or UMI-based scRNA-seq techniques, like SMART-Seq2. Given a set of mixture samples $M$, the approach creates a series of estimated mixture samples $M'$, where the latter consists of a linear combination of imputed cell type proportions in $M$ along with the corresponding signature matrix profiles (in non-log linear space). Although the strategy is general and can flexibly accommodate different deconvolution and batch correction methods, we used ComBat \(^14\) (an empirical Bayesian method) to eliminate technical variation between $M$ and $M'$ after log-reg. adjustment. Once cross-platform variation has been minimized, cell proportions are re-estimated using the adjusted mixture samples in non-log linear space. In addition to cell type enumeration, this approach can also be applied to cell-type-specific gene expression purification, allowing the down-weighting of genes whose expression levels are low or absent from the collection of cell types in the signature matrix. An absolute minimum of three mixture samples is required to perform the batch correction procedure, though at least ten is recommended. We found that application of this strategy to LM22, a microarray-derived signature matrix, results in improved deconvolution performance across multiple datasets and platforms (Supplementary Fig. 2d).

S-mode. Despite the benefits of the above technique, deconvolution may fail when excessive technical variance is present (for example, batches that are expected to be present are observed to drop out) in bulk GEP samples after deconvolution. In this study, we observed this phenomenon when using signature matrices derived from 10x Chromium without batch correction (Fig. 2b and Supplementary Fig. 1d,k). This discrepancy was not surprising, given the major differences in transcriptome representation between UMI-based and 3’/5’-based methods, such as 10x Chromium and those that capture full transcripts without UMI’s, such as SMART-Seq2 (Fig. S3E in Ziegenhain et al. \(^15\)). Because B-mode requires an initial round of fractional abundance estimates prior to normalization, it inherently cannot address cellular dropout and is insufficient to overcome excessive variation (Supplementary Fig. 1d). We therefore developed a second strategy for single-cell batch correction (S-mode), tailored for signature matrices derived from droplet-based or UMI-based scRNA-seq techniques, including 10x Chromium, but also applicable to other challenging datasets (Supplementary Fig. 1b).

Like B-mode, the primary objective of S-mode is to obtain cell frequencies from a set of mixture GEPs while minimizing technical variation. However, unlike B-mode, S-mode directly adjusts the signature matrix rather than the mixture matrix. We found that this strategy delivered superior performance on datasets with considerable technical variation (for example, Supplementary Fig. 1d). Details of S-mode are provided in Supplementary Note 1, and validation data are shown in Supplementary Fig. 2a–c.

Software implementation and website. CIBERSORTx was developed within a web framework with its back-end based on R and PHP and hosted at http://cibersortx.stanford.edu. This web framework minimizes inherent dependencies on specific hardware, software packages and libraries and file-system attributes. Users are presented with a detailed guide employing several
step-by-step tutorials and allowing the recreation of key figures in this work, including for each step depicted in Fig. 1. Through this interface, CIBERSORTx allows users to process gene expression data representing a bulk admixture of different cell types, along with (1) a signature gene file that enumerates the genes defining the expression profile for each cell type of interest. For the latter, users can either use existing/curated signature matrices for reference cell types or create custom signature gene files by providing the reference gene expression profiles of pure cell populations. Specifically, to create a custom signature gene matrix, users can provide scRNA-seq data or data from bulk sorted samples, along with the phenotypic identities of single cell types or cell populations of interest.

Given these input files, CIBERSORTx allows (2) imputation of the fractional representations of each cell type present in the mixture, similarly to its predecessor. However, unlike CIBERSORT, CIBERSORTx now supports deconvolution from bulk RNA-seq data by implementing the critical batch correction methods described above. CIBERSORTx also allows imputation of GEPs for individual in silico purified cell types in two distinct modes, as described above (that is, (3) group-mode and (4) high-resolution). The resulting imputed cell fractions and imputed cell-type-specific GEPs are then rendered as heat maps, tables and stacked bar plots for visualization and downloading. In addition, customizable t-SNE plots are automatically generated for high-resolution purification results.

The interactive CIBERSORTx user interface is powered by the jQuery JavaScript library and various open source libraries (including phpMailer, idiomr, blueimp jQuery-File-Upload, DataTables, PHPExcel and mPDF), with the graphical user interface of the website powered by Twitter Bootstrap v.2.3.2 and R Shiny. The site runs on an Apache server on a virtual machine and stores user and job data in a MySQL database. However, users have complete control over their data and can delete them at will. Each user’s environment includes example datasets used for benchmarking, tutorials for the use of CIBERSORTx and preparation of input data and other example files.

**Statistical analysis.** Linear concordance between known and predicted cell type features (proportions or GEPs) was determined by Pearson correlation (r), Spearman correlation (ρ) or linear regression (R²), as indicated, and a two-sided t-test was used to assess whether the result was significantly non-zero. Lin’s concordance correlation coefficient (CCC) was determined by comparing predicted and expected log-adjusted expression profiles using the CCC function from the R package, DescTools. When data were normally distributed, group comparisons were determined using a two-sided t-test with unequal variance or a paired t-test, as appropriate; otherwise, a two-sided Wilcoxon test was applied. Multiple hypothesis testing was performed using the Benjamini and Hochberg method unless stated otherwise. Results with P < 0.05 were considered significant. Statistical analyses were performed with R and Prism v.7 (GraphPad Software, Inc.). The investigators were not blinded to allocation during experiments and outcome assessment. No sample-size estimates were performed to ensure adequate power to detect a prespecified effect size.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**Data availability**

All expression datasets analyzed in this work, including accession codes, file names and web links (if available), are listed in Supplementary Table 1. Expression data generated in this study are available at http://cibersortx.stanford.edu and through the Gene Expression Omnibus with accession code GSE127472.

**Code availability**

CIBERSORTx v.1.0 was used to generate the results in this work and is freely available for academic research use at http://cibersortx.stanford.edu.

**References**

63. Levy, R. et al. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J. Clin. Oncol. **32**, 1797–1803 (2014).
64. Allantaz, F. et al. Expression profiling of human immune cell subsets identifies miRNA-mRNA regulatory relationships correlated with cell type specific expression. PLoS ONE **7**, e99779 (2012).
65. Compagno, M. et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature **459**, 717–721 (2009).
66. Jourdan, M. et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood **114**, 5173–5181 (2009).
67. Kiaii, S. et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J. Clin. Oncol. **31**, 2654–2661 (2013).
68. Nakaya, H. I. et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. **12**, 786–795 (2011).
69. Tatlow, P. J. & Piccolo, S. R. A cloud-based workflow to quantify transcript-expression levels in public cancer compendia. Sci. Rep. **6**, 39259 (2016).
70. Milpied, P. et al. Germinal center program de-synchronization and intra-patient heterogeneity in follicular lymphoma B-cells revealed by integrative single-cell analysis. Blood **130**, 41–47 (2017).
71. Vallejos, C. A., Risco, D., Scialdone, A., Dudoit, S. & Marioni, J. C. Normalizing single-cell RNA sequencing data: challenges and opportunities. Nat. Methods **14**, 565–571 (2017).
72. Stegle, O., Teichmann, S. A. & Marioni, J. C. Computational and analytical challenges in single-cell transcriptomics. Nat. Rev. Genet. **16**, 133–145 (2015).
73. Hicks, S. C., Townes, F. W., Teng, M. & Irizarry, R. A. Missing data and technical variability in single-cell RNA-seq experiments. Biostatistics, **9**, 562–578 (2018).
74. Venet, D., Pecasse, F., Maenhaut, C. & Bersini, H. Separation of samples into their constituents using gene expression data. Bioinformatics **17**(Suppl. 1), S279–S287 (2001).
75. Abbas, A. R., Woldeleg, K., Seshasayee, D., Modrusan, Z. & Clark, H. F. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS ONE **4**, e6998 (2009).
76. Zhong, Y. & Liu, Z. Gene expression deconvolution in linear space. Nat. Methods **9**, 8–9 (2012); author reply 9, 9 (2012).
77. Lee, D. D. & Seung, H. S. Algorithms for non-negative matrix factorization. In Proc. 13th International Conference on Neural Information Processing Systems (eds. Leen, T.K. et al.) 535–541 (MIT Press, 2000).
78. Racher, R. et al. SCNnorm: robust normalization of single-cell RNA-seq data. Nat. Methods **14**, 584 (2017).
79. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics **8**, 118–127 (2007).
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
- Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

- Data collection
  - FlowJo version 10.4

- Data analysis
  - Cell Ranger v1.2, Graphpad Prism v7, CIBERSORTx v1.0 (http://cibersortx.stanford.edu), and publicly available software, including various R packages (e.g., tximport, affy, Rtsne, sva [ComBat], bapred, Seurat v1.4.0.16).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The authors declare that the data supporting the findings of this study are available within the paper [and its supplementary information files].

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences
Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | No sample-size estimates were performed to ensure adequate power to detect a pre-specified effect size. However, our conclusions are supported by a wide variety of technical and clinically-relevant benchmarking experiments, several of which contained a large number of samples (e.g., FL samples in Fig. 3) and all of which were analyzed and interpreted using statistically appropriate techniques, as described in Online Methods. |
| Data exclusions | Some sequencing libraries were excluded due to quality control considerations, as described in Online Methods and indicated in Supplementary Table 1. No exclusion criteria were pre-established. |
| Replication | All attempts at replication were successful. |
| Randomization | Sample groups were determined according to the experimental question and known or predetermined biological or clinical phenotypes (e.g., GCB vs ABC DLBCL). No randomization was applied. |
| Blinding | The investigators were not blinded to group allocation during data collection or analysis. However, the CIBERSORTx high resolution purification algorithm was not explicitly provided with group labels. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

| n/a | Involved in the study |
|-----|-----------------------|
| x   | Antibodies            |
|     | Eukaryotic cell lines |
| x   | Palaeontology         |
|     | Animals and other organisms |
|     | Human research participants |
|     | Clinical data         |

### Methods

| n/a | Involved in the study |
|-----|-----------------------|
| x   | ChIP-seq              |
|     | Flow cytometry        |
|     | MRI-based neuroimaging |

### Antibodies

**Antibodies used**

Freshly resected surgical tumor samples from patients with NSCLC were dissociated and sorted as previously described (PMIDs 26193342, 26286589) using A700 anti-human CD45 clone HI30 (pan-leukocyte cell marker), PE anti-human CD31 clone XWM59 (endothelial cell marker), APC anti-human EpCAM clone X9C4 (epithelial cell marker), and PE-Cy7 anti-human CD10 clone XHI10a (fibroblast marker). All antibodies were obtained from BioLegend.

**Validation**

Antibodies were validated by the manufacturer.

### Human research participants

**Policy information about** [studies involving human research participants](#) **Policy information about** [studies involving human research participants](#)

**Population characteristics**

For a patient with metastatic NSCLC treated with an immune checkpoint inhibitor (Pembrolizumab, Merck), peripheral blood was obtained on the first day of treatment prior to infusion (NCT00349830 and NCT02955758). Fresh tumor biopsies from patients with early stage NSCLC were obtained during routine primary surgical resection. Fresh or frozen surgical biopsies of follicular lymphoma tumors were obtained from previously untreated FL patients enrolled in a phase III clinical trial (NCT0001729063), as well as from patients seen as part of the Stanford University Lymphoma Program Project (NCT00398177). Whole blood samples from 12 healthy adult donors were obtained from the Stanford Blood Center.

**Recruitment**

Recruitment criteria are described at http://www.clinicaltrials.gov for the trials noted above.

**Ethics oversight**

All patient samples in this study were collected with informed consent for research use and were approved by the Stanford Institutional Review Board in accordance with the Declaration of Helsinki.

Note that full information on the approval of the study protocol must also be provided in the manuscript.
Flow Cytometry

Plots

Confirm that:

☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
☐ All plots are contour plots with outliers or pseudocolor plots.
☐ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation
Freshly resected surgical tumor samples from patients with NSCLC were dissociated and sorted as previously described (PMIDs 26286589, 26193342). Cryopreserved FL tumor cell suspensions were thawed, processed, and sorted to isolate CD5–CD19+ B cells as previously described (PMID 25713363).

Instrument
FACSAria III flow cytometer instrument (BD Biosciences).

Software
Flow cytometry data were collected with BD FACSDIVA software version 8.0.1 from BD Biosciences and analyzed by FlowJo version 10.4.

Cell population abundance
NSCLC PBMCs were not sorted, but were profiled by scRNA-seq (10x Genomics). Purities of NSCLC tumor subsets and FL B cells were assessed as previously described (PMIDs 26286589, 26193342, 25713363).

Gating strategy
Live/dead discrimination was performed using standard FSC vs SSC gating. NSCLC cell subsets from solid tumors and purified B cells from FL tumors were additionally gated as described previously (PMIDs 26286589, 26193342, 25713363).

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.